{"id":"poractant-alfa","rwe":[],"_fda":{"id":"6b713a41-2648-43f4-9a10-cc41a7e83ca0","set_id":"99bef307-00bd-4379-9f45-ede1380e74d4","openfda":{"nui":["N0000008294","N0000175778","N0000000079"],"unii":["KE3U2023NP"],"route":["ENDOTRACHEAL"],"rxcui":["259216","261329"],"spl_id":["6b713a41-2648-43f4-9a10-cc41a7e83ca0"],"brand_name":["Curosurf"],"spl_set_id":["99bef307-00bd-4379-9f45-ede1380e74d4"],"package_ndc":["10122-510-03","10122-510-01"],"product_ndc":["10122-510"],"generic_name":["PORACTANT ALFA"],"product_type":["HUMAN PRESCRIPTION DRUG"],"pharm_class_pe":["Alveolar Surface Tension Reduction [PE]"],"substance_name":["PORACTANT ALFA"],"pharm_class_epc":["Surfactant [EPC]"],"pharm_class_moa":["Surfactant Activity [MoA]"],"manufacturer_name":["Chiesi USA, Inc."],"application_number":["BLA020744"],"is_original_packager":[true]},"version":"45","overdosage":["10 OVERDOSAGE There have been no reports of overdosage following the administration of CUROSURF. In the event of accidental overdosage, and if there are clear clinical effects on the infant's respiration, ventilation, or oxygenation, aspirate as much of the suspension as possible and provide the infant with supportive treatment, with particular attention to fluid and electrolyte balance."],"description":["11 DESCRIPTION Poractant alfa is an extract of natural porcine lung (pulmonary) surfactant consisting of 99% polar lipids (mainly phospholipids) and 1% hydrophobic low molecular weight surfactant associated proteins (SP). The molecular weight of SP-B is 8.7 KDa and the molecular weight of SP-C is 3.7 KDa. CUROSURF (poractant alfa) intratracheal suspension is a sterile, white to creamy white suspension provided in a single-dose vial for intratracheal use. Each milliliter of suspension contains 80 mg of poractant alfa (surfactant extract) that includes 76 mg of phospholipids and 1 mg of SP of which 0.45 mg is SP-B, a 79-amino acid protein and 0.59 mg is SP-C, a 35-amino acid peptide . The amount of phospholipids is calculated from the content of phosphorus and contains 55 mg of phosphatidylcholine of which 30 mg is dipalmitoylphosphatidylcholine. It is suspended in 0.9% sodium chloride solution. The pH is adjusted with sodium bicarbonate to a pH of 6.2 (5.5 to 6.5). Curosurf contains no preservatives."],"how_supplied":["16 HOW SUPPLIED/STORAGE AND HANDLING CUROSURF (poractant alfa) intratracheal suspension is a white to creamy white suspension available in sterile, rubber-stoppered clear glass vials containing (one vial per carton): 120 mg/1.5 mL (80 mg/mL) poractant alfa (surfactant extract) of suspension: NDC Number: 10122-510-01 240 mg/3 mL (80 mg/mL) poractant alfa (surfactant extract) of suspension. NDC Number: 10122-510-03 Store CUROSURF intratracheal suspension in a refrigerator at +2°C to +8°C (36°F to 46°F). PROTECT FROM LIGHT. Do not shake. Vials are for single-dose only. After opening the vial discard the unused portion [see Dosage and Administration ( 2.3 )]. Manufactured by: Chiesi USA, Inc. Cary, NC 27518 U.S.License No. 2150 Manufactured at and licensed from: Chiesi Farmaceutici, S.p.A. Parma, Italy 43100 CTC-007-0320-03-SPL-2"],"pediatric_use":["8.4 Pediatric Use The safety and effectiveness of CUROSURF for the rescue treatment, including the reduction of mortality and pneumothoraces, of Respiratory Distress Syndrome (RDS) have been established in premature infants and the information on this use is discussed throughout the labeling. The safety and effectiveness of CUROSURF in the treatment of full term infants or older pediatric patients with respiratory failure has not been established."],"effective_time":"20251210","clinical_studies":["14 CLINICAL STUDIES 14.1 Rescue Treatment of Respiratory Distress Syndrome The clinical efficacy of CUROSURF in the treatment of established Respiratory Distress Syndrome (RDS) in premature infants was demonstrated in one single-dose study (Study 1) and one multiple-dose study (Study 2) involving approximately 500 infants. Each study was randomized, multicenter, and controlled. In study 1, premature infants 700 to 2000 grams birth weight with RDS requiring mechanical ventilation and a FiO 2 ≥ 0.60 were enrolled. CUROSURF 2.5 mL/kg single dose (200 mg/kg) or control (disconnection from the ventilator and manual ventilation for 2 minutes) was administered after RDS developed and before 15 hours of age. The results from Study 1 are shown below in Table 2. Table 2: Study 1 Results in Premature Infants with Respiratory Distress Syndrome Efficacy Parameter Single DoseCUROSURFn=78 Controln=67 p-Value Mortality at 28 Days (All Causes) 31% 48% ≤0.05 Bronchopulmonary Dysplasia* 18% 22% N.S. Pneumothorax 21% 36% ≤0.05 Pulmonary Interstitial Emphysema 21% 38% ≤0.05 *Bronchopulmonary dysplasia (BPD) diagnosed by positive x-ray and supplemental oxygen dependence at 28 days of life. N.S.: not statistically significant In Study 2, premature infants 700 to 2000 g birth weight with RDS requiring mechanical ventilation and a FiO 2 ≥ 0.60 were enrolled. In this two-arm trial, CUROSURF was administered after RDS developed and before 15 hours of age, as a single-dose or as multiple doses. In the single-dose arm, infants received CUROSURF 2.5 mL/kg (200 mg/kg). In the multiple-dose arm, the initial dose of CUROSURF was 2.5 mL/kg followed by up to two 1.25 mL/kg (100 mg/kg) doses of CUROSURF. The results from Study 2 are shown below in Table 3. Table 3: Study 2 Results in Premature Infants with Respiratory Distress Syndrome Efficacy Parameter Single DoseCUROSURFn=184Rate (%) Multiple DoseCUROSURFn=173Rate (%) p-Value Mortality at 28 Days (All Causes) 21 13 0.048 Bronchopulmonary Dysplasia* 18 18 N.S. Pneumothorax 17 9 0.03 Pulmonary Interstitial Emphysema 27 22 N.S. *Bronchopulmonary dysplasia (BPD) diagnosed by positive x-ray and supplemental oxygen dependence at 28 days of life. N.S.: not statistically significant There is no controlled experience on the effects of administering initial doses of CUROSURF other than 2.5 mL/kg (200 mg/kg), subsequent doses other than 1.25 mL/kg (100 mg/kg), administration of more than three total doses, dosing more frequently than every 12 hours, or initiating therapy with CUROSURF more than 15 hours after diagnosing RDS. Adequate data are not available on the use of CUROSURF in conjunction with experimental therapies of RDS, e.g., high-frequency ventilation or extracorporeal membrane oxygenation.","14.1 Rescue Treatment of Respiratory Distress Syndrome The clinical efficacy of CUROSURF in the treatment of established Respiratory Distress Syndrome (RDS) in premature infants was demonstrated in one single-dose study (Study 1) and one multiple-dose study (Study 2) involving approximately 500 infants. Each study was randomized, multicenter, and controlled. In study 1, premature infants 700 to 2000 grams birth weight with RDS requiring mechanical ventilation and a FiO 2 ≥ 0.60 were enrolled. CUROSURF 2.5 mL/kg single dose (200 mg/kg) or control (disconnection from the ventilator and manual ventilation for 2 minutes) was administered after RDS developed and before 15 hours of age. The results from Study 1 are shown below in Table 2. Table 2: Study 1 Results in Premature Infants with Respiratory Distress Syndrome Efficacy Parameter Single DoseCUROSURFn=78 Controln=67 p-Value Mortality at 28 Days (All Causes) 31% 48% ≤0.05 Bronchopulmonary Dysplasia* 18% 22% N.S. Pneumothorax 21% 36% ≤0.05 Pulmonary Interstitial Emphysema 21% 38% ≤0.05 *Bronchopulmonary dysplasia (BPD) diagnosed by positive x-ray and supplemental oxygen dependence at 28 days of life. N.S.: not statistically significant In Study 2, premature infants 700 to 2000 g birth weight with RDS requiring mechanical ventilation and a FiO 2 ≥ 0.60 were enrolled. In this two-arm trial, CUROSURF was administered after RDS developed and before 15 hours of age, as a single-dose or as multiple doses. In the single-dose arm, infants received CUROSURF 2.5 mL/kg (200 mg/kg). In the multiple-dose arm, the initial dose of CUROSURF was 2.5 mL/kg followed by up to two 1.25 mL/kg (100 mg/kg) doses of CUROSURF. The results from Study 2 are shown below in Table 3. Table 3: Study 2 Results in Premature Infants with Respiratory Distress Syndrome Efficacy Parameter Single DoseCUROSURFn=184Rate (%) Multiple DoseCUROSURFn=173Rate (%) p-Value Mortality at 28 Days (All Causes) 21 13 0.048 Bronchopulmonary Dysplasia* 18 18 N.S. Pneumothorax 17 9 0.03 Pulmonary Interstitial Emphysema 27 22 N.S. *Bronchopulmonary dysplasia (BPD) diagnosed by positive x-ray and supplemental oxygen dependence at 28 days of life. N.S.: not statistically significant There is no controlled experience on the effects of administering initial doses of CUROSURF other than 2.5 mL/kg (200 mg/kg), subsequent doses other than 1.25 mL/kg (100 mg/kg), administration of more than three total doses, dosing more frequently than every 12 hours, or initiating therapy with CUROSURF more than 15 hours after diagnosing RDS. Adequate data are not available on the use of CUROSURF in conjunction with experimental therapies of RDS, e.g., high-frequency ventilation or extracorporeal membrane oxygenation."],"pharmacodynamics":["12.2 Pharmacodynamics In vitro - CUROSURF lowers minimum surface tension to ≤ 4mN/m as measured by the Wilhelmy Balance System."],"pharmacokinetics":["12.3 Pharmacokinetics CUROSURF is administered directly to the lung, where biophysical effects occur at the alveolar surface. No human pharmacokinetic studies have been performed to characterize the absorption, biotransformation, or elimination of CUROSURF."],"adverse_reactions":["6 ADVERSE REACTIONS Common adverse reactions associated with the administration of CUROSURF include bradycardia, hypotension, endotracheal tube blockage, and oxygen desaturation. ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Chiesi USA, Inc. at 1-888-661-9260 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice. Adverse Reactions in Studies in Premature Infants with Respiratory Distress Syndrome The safety data described below reflect exposure to CUROSURF at a single dose of 2.5 mL/kg (200 mg/kg), in 78 infants of 700-2000 grams birth weight with RDS requiring mechanical ventilation and a FiO 2 ≥ 0.60 (Study 1) [see Clinical Studies ( 14.1 )]. A total of 144 infants were studied after RDS developed and before 15 hours of age; 78 infants received CUROSURF 2.5 mL/kg single dose (200 mg/kg), and 66 infants received control treatment (disconnection from the ventilator and manual ventilation for 2 minutes). Transient adverse reactions seen with the administration of CUROSURF included bradycardia, hypotension, endotracheal tube blockage, and oxygen desaturation. The rates of the most common serious complications associated with prematurity and RDS observed in Study 1 are shown in Table 1. Table 1: Most Common Serious Complications Associated with Prematurity and RDS in Study 1 CUROSURF 2.5 mL/kgn=78 CONTROL*n=66 Acquired Pneumonia 17% 21% Acquired Septicemia 14% 18% Bronchopulmonary Dysplasia 18% 22% Intracranial Hemorrhage 51% 64% Patent Ductus Arteriosus 60% 48% Pneumothorax 21% 36% Pulmonary Interstitial Emphysema 21% 38% *Control patients were disconnected from the ventilator and manually ventilated for 2 minutes. No surfactant was instilled. Seventy-six infants (45 treated with CUROSURF) from study 1 were evaluated at 1 year of age and 73 infants (44 treated with CUROSURF) were evaluated at 2 years of age to assess for potential long-term adverse reactions. Data from follow-up evaluations for weight and length, persistent respiratory symptoms, incidence of cerebral palsy, visual impairment, or auditory impairment was similar between treatment groups. In 16 patients (10 treated with CUROSURF and 6 controls) evaluated at 5.5 years of age, the developmental quotient, derived using the Griffiths Mental Developmental Scales, was similar between groups. 6.2 Immunogenicity Immunological studies have not demonstrated differences in levels of surfactant-anti-surfactant immune complexes and anti-CUROSURF antibodies between patients treated with CUROSURF and patients who received control treatment. 6.3 Postmarketing Experience Pulmonary hemorrhage, a known complication of premature birth and very low birth-weight, has been reported both in clinical trials with CUROSURF and in postmarketing adverse event reports in infants who had received CUROSURF.","6.1 Clinical Trials Experience Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice. Adverse Reactions in Studies in Premature Infants with Respiratory Distress Syndrome The safety data described below reflect exposure to CUROSURF at a single dose of 2.5 mL/kg (200 mg/kg), in 78 infants of 700-2000 grams birth weight with RDS requiring mechanical ventilation and a FiO 2 ≥ 0.60 (Study 1) [see Clinical Studies ( 14.1 )]. A total of 144 infants were studied after RDS developed and before 15 hours of age; 78 infants received CUROSURF 2.5 mL/kg single dose (200 mg/kg), and 66 infants received control treatment (disconnection from the ventilator and manual ventilation for 2 minutes). Transient adverse reactions seen with the administration of CUROSURF included bradycardia, hypotension, endotracheal tube blockage, and oxygen desaturation. The rates of the most common serious complications associated with prematurity and RDS observed in Study 1 are shown in Table 1. Table 1: Most Common Serious Complications Associated with Prematurity and RDS in Study 1 CUROSURF 2.5 mL/kgn=78 CONTROL*n=66 Acquired Pneumonia 17% 21% Acquired Septicemia 14% 18% Bronchopulmonary Dysplasia 18% 22% Intracranial Hemorrhage 51% 64% Patent Ductus Arteriosus 60% 48% Pneumothorax 21% 36% Pulmonary Interstitial Emphysema 21% 38% *Control patients were disconnected from the ventilator and manually ventilated for 2 minutes. No surfactant was instilled. Seventy-six infants (45 treated with CUROSURF) from study 1 were evaluated at 1 year of age and 73 infants (44 treated with CUROSURF) were evaluated at 2 years of age to assess for potential long-term adverse reactions. Data from follow-up evaluations for weight and length, persistent respiratory symptoms, incidence of cerebral palsy, visual impairment, or auditory impairment was similar between treatment groups. In 16 patients (10 treated with CUROSURF and 6 controls) evaluated at 5.5 years of age, the developmental quotient, derived using the Griffiths Mental Developmental Scales, was similar between groups.","6.2 Immunogenicity Immunological studies have not demonstrated differences in levels of surfactant-anti-surfactant immune complexes and anti-CUROSURF antibodies between patients treated with CUROSURF and patients who received control treatment.","6.3 Postmarketing Experience Pulmonary hemorrhage, a known complication of premature birth and very low birth-weight, has been reported both in clinical trials with CUROSURF and in postmarketing adverse event reports in infants who had received CUROSURF."],"contraindications":["4 CONTRAINDICATIONS None. None."],"mechanism_of_action":["12.1 Mechanism of Action Endogenous pulmonary surfactant reduces surface tension at the air-liquid interface of the alveoli during ventilation and stabilizes the alveoli against collapse at resting transpulmonary pressures. A deficiency of pulmonary surfactant in preterm infants results in Respiratory Distress Syndrome (RDS) characterized by poor lung expansion, inadequate gas exchange, and a gradual collapse of the lungs (atelectasis). CUROSURF compensates for the deficiency of surfactant and restores surface activity to the lungs of these infants."],"clinical_pharmacology":["12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Endogenous pulmonary surfactant reduces surface tension at the air-liquid interface of the alveoli during ventilation and stabilizes the alveoli against collapse at resting transpulmonary pressures. A deficiency of pulmonary surfactant in preterm infants results in Respiratory Distress Syndrome (RDS) characterized by poor lung expansion, inadequate gas exchange, and a gradual collapse of the lungs (atelectasis). CUROSURF compensates for the deficiency of surfactant and restores surface activity to the lungs of these infants. 12.2 Pharmacodynamics In vitro - CUROSURF lowers minimum surface tension to ≤ 4mN/m as measured by the Wilhelmy Balance System. 12.3 Pharmacokinetics CUROSURF is administered directly to the lung, where biophysical effects occur at the alveolar surface. No human pharmacokinetic studies have been performed to characterize the absorption, biotransformation, or elimination of CUROSURF."],"indications_and_usage":["1 INDICATIONS AND USAGE CUROSURF ® (poractant alfa) Intratracheal Suspension is indicated for the rescue treatment of Respiratory Distress Syndrome (RDS) in premature infants. CUROSURF reduces mortality and pneumothoraces associated with RDS. CUROSURF is a surfactant indicated for the rescue treatment, including the reduction of mortality and pneumothoraces, of Respiratory Distress Syndrome (RDS) in premature infants. ( 1 )"],"warnings_and_cautions":["5 WARNINGS AND PRECAUTIONS Acute Changes in Lung Compliance : Frequently assess need to modify oxygen and ventilatory support to respiratory changes ( 5.1 ) Administration-Related Adverse Reactions : Transient adverse effects include bradycardia, hypotension, endotracheal tube blockage, and oxygen desaturation. These events require stopping CUROSURF administration and taking appropriate measures to alleviate the condition ( 5.2 ) 5.1 Acute Changes in Oxygenation and Lung Compliance The administration of exogenous surfactants, including CUROSURF, can rapidly affect oxygenation and lung compliance. Therefore, infants receiving CUROSURF should receive frequent clinical and laboratory assessments so that oxygen and ventilatory support can be modified to respond to respiratory changes. CUROSURF should only be administered by those trained and experienced in the care, resuscitation, and stabilization of pre-term infants. 5.2 Administration-Related Adverse Reactions Transient adverse reactions associated with administration of CUROSURF include bradycardia, hypotension, endotracheal tube blockage, and oxygen desaturation. These events require stopping CUROSURF administration and taking appropriate measures to alleviate the condition. After the patient is stable, dosing may proceed with appropriate monitoring.","5.1 Acute Changes in Oxygenation and Lung Compliance The administration of exogenous surfactants, including CUROSURF, can rapidly affect oxygenation and lung compliance. Therefore, infants receiving CUROSURF should receive frequent clinical and laboratory assessments so that oxygen and ventilatory support can be modified to respond to respiratory changes. CUROSURF should only be administered by those trained and experienced in the care, resuscitation, and stabilization of pre-term infants.","5.2 Administration-Related Adverse Reactions Transient adverse reactions associated with administration of CUROSURF include bradycardia, hypotension, endotracheal tube blockage, and oxygen desaturation. These events require stopping CUROSURF administration and taking appropriate measures to alleviate the condition. After the patient is stable, dosing may proceed with appropriate monitoring."],"clinical_studies_table":["
Efficacy ParameterSingle DoseCUROSURFn=78Controln=67p-Value
Mortality at 28 Days (All Causes)31%48%≤0.05
Bronchopulmonary Dysplasia*18%22%N.S.
Pneumothorax21%36%≤0.05
Pulmonary Interstitial Emphysema21%38%≤0.05
","
Efficacy ParameterSingle DoseCUROSURFn=184Rate (%)Multiple DoseCUROSURFn=173Rate (%)p-Value
Mortality at 28 Days (All Causes)21130.048
Bronchopulmonary Dysplasia*1818N.S.
Pneumothorax1790.03
Pulmonary Interstitial Emphysema2722N.S.
","
Efficacy ParameterSingle DoseCUROSURFn=78Controln=67p-Value
Mortality at 28 Days (All Causes)31%48%≤0.05
Bronchopulmonary Dysplasia*18%22%N.S.
Pneumothorax21%36%≤0.05
Pulmonary Interstitial Emphysema21%38%≤0.05
","
Efficacy ParameterSingle DoseCUROSURFn=184Rate (%)Multiple DoseCUROSURFn=173Rate (%)p-Value
Mortality at 28 Days (All Causes)21130.048
Bronchopulmonary Dysplasia*1818N.S.
Pneumothorax1790.03
Pulmonary Interstitial Emphysema2722N.S.
"],"nonclinical_toxicology":["13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Studies to assess potential carcinogenic effects of CUROSURF have not been conducted. Poractant alfa was negative for genotoxicity in the following assays: bacterial reverse mutation assay (Ames test), gene mutation assay in Chinese hamster V79 cells, chromosomal aberration assay in Chinese hamster ovary cells, unscheduled DNA synthesis in HELA S3 cells, and in vivo mouse micronucleus assay. No studies to assess reproductive effects of CUROSURF have been performed."],"adverse_reactions_table":["
CUROSURF 2.5 mL/kgn=78CONTROL*n=66
Acquired Pneumonia17%21%
Acquired Septicemia14%18%
Bronchopulmonary Dysplasia18%22%
Intracranial Hemorrhage51%64%
Patent Ductus Arteriosus60%48%
Pneumothorax21%36%
Pulmonary Interstitial Emphysema21%38%
","
CUROSURF 2.5 mL/kgn=78CONTROL*n=66
Acquired Pneumonia17%21%
Acquired Septicemia14%18%
Bronchopulmonary Dysplasia18%22%
Intracranial Hemorrhage51%64%
Patent Ductus Arteriosus60%48%
Pneumothorax21%36%
Pulmonary Interstitial Emphysema21%38%
"],"dosage_and_administration":["2 DOSAGE AND ADMINISTRATION Before administering CUROSURF, assure proper placement and patency of endotracheal tube ( 2.1 ) Administer intratracheally either in ( 2.1 ): Two divided aliquots through a 5 French end-hole catheter; or A single bolus through secondary lumen of a dual lumen endotracheal tube without interrupting mechanical ventilation Initial recommended dose is 2.5 mL/kg birth weight ( 2.2 ) Up to two repeat doses of 1.25 mL/kg birth weight may be administered at approximately 12-hour intervals ( 2.2 ) Maximum total dose (initial plus repeat doses) is 5 mL/kg ( 2.2 ) See Full Prescribing Information for instructions on preparation and administration of the CUROSURF suspension ( 2.3 , 2.4 ) 2.1 Important Administration Instructions For intratracheal administration only. CUROSURF should be administered by, or under the supervision of clinicians experienced in intubation, ventilator management, and general care of premature infants. Before administering CUROSURF, assure proper placement and patency of the endotracheal tube. At the discretion of the clinician, the endotracheal tube may be suctioned before administering CUROSURF. Allow the infant to stabilize before proceeding with dosing. Administer CUROSURF either: Intratracheally by instillation in two divided aliquots through a 5 French end-hole catheter or Intratracheally in a single bolus through the secondary lumen of a dual lumen endotracheal tube without interrupting mechanical ventilation. 2.2 Recommended Dosage The initial recommended dose is 2.5 mL/kg birth weight, administered as one or two aliquots depending upon the instillation procedure [see Dosage and Administration ( 2.4 )]. Up to two repeat doses of 1.25 mL/kg birth weight each may be administered at approximately 12-hour intervals in infants in whom RDS is considered responsible for their persisting or deteriorating respiratory status. The maximum recommended total dosage (sum of the initial and up to two repeat doses) is 5 mL/kg. 2.3 Preparation of the CUROSURF Suspension Remove the vial of CUROSURF suspension from a refrigerator at +2°C to +8°C (36°F to 46°F) and slowly warm the vial to room temperature before use. Visually inspect the CUROSURF suspension for discoloration prior to administration. The color of the CUROSURF suspension should be white to creamy white. Discard the CUROSURF vial if the suspension is discolored. Gently turn the vial upside-down, in order to obtain a uniform suspension. DO NOT SHAKE. Locate the notch (FLIP UP) on the colored plastic cap and lift the notch and pull upwards. Pull the plastic cap with the aluminum portion downwards. Remove the whole ring by pulling off the aluminum wrapper. Remove the rubber cap to extract content. Unopened, unused vials of CUROSURF suspension that have warmed to room temperature can be returned to refrigerated storage within 24 hours for future use. Do not warm to room temperature and return to refrigerated storage more than once. Protect from light. 2.4 Administration For endotracheal tube instillation using a 5 French end-hole catheter Slowly withdraw the entire contents of the vial of CUROSURF suspension into a 3 or 5 mL plastic syringe through a large-gauge needle (e.g., at least 20 gauge). Enter each single-use vial only once. Attach the 5 French end-hole catheter of appropriate length to position the catheter tip proximal to the distal portion of the endotracheal tube, to the syringe. Fill the catheter with CUROSURF suspension. Discard excess CUROSURF through the catheter so that only the dose to be given remains in the syringe. For the first dose: 1.25 mL/kg (birth weight) per aliquot For each repeated dose: 0.625 mL/kg (birth weight) per aliquot First aliquot of CUROSURF suspension: Position the infant in a neutral position (head and body in alignment without inclination), with either the right or left side dependent. Immediately before CUROSURF administration, ventilate the infant with supplemental oxygen sufficient to maintain SaO 2 > 92%. Insert the catheter into the endotracheal tube and instill the first aliquot of CUROSURF suspension. After the first aliquot is instilled, remove the catheter from the endotracheal tube and manually ventilate with supplemental oxygen until clinically stable. Second aliquot of CUROSURF suspension: When the infant is stable, reposition the infant such that the other side is dependent. Administer the remaining aliquot using the same procedures as the first aliquot. After completion of the dosing procedure, do not suction airways for 1 hour after surfactant instillation unless signs of significant airway obstruction occur [see Clinical Studies ( 14.1 )] . For endotracheal tube instillation using the secondary lumen of a dual lumen endotracheal tube Slowly withdraw the entire contents of the vial of CUROSURF suspension into a 3 or 5 mL plastic syringe through a large-gauge needle (e.g., at least 20 gauge). Do not attach 5 French end-hole catheter. Remove the needle and discard excess CUROSURF so that only the dose to be given remains in the syringe. Keep the infant in a neutral position (head and body in alignment without inclination). Administer CUROSURF suspension through the proximal end of the secondary lumen of the endotracheal tube as a single dose, given over 1 minute, and without interrupting mechanical ventilation. After completion of this dosing procedure, ventilator management may require transient increases in FiO 2 , ventilator rate, or PIP. Do not suction airways for 1 hour after surfactant instillation unless signs of significant airway obstruction occur.","2.1 Important Administration Instructions For intratracheal administration only. CUROSURF should be administered by, or under the supervision of clinicians experienced in intubation, ventilator management, and general care of premature infants. Before administering CUROSURF, assure proper placement and patency of the endotracheal tube. At the discretion of the clinician, the endotracheal tube may be suctioned before administering CUROSURF. Allow the infant to stabilize before proceeding with dosing. Administer CUROSURF either: Intratracheally by instillation in two divided aliquots through a 5 French end-hole catheter or Intratracheally in a single bolus through the secondary lumen of a dual lumen endotracheal tube without interrupting mechanical ventilation.","2.2 Recommended Dosage The initial recommended dose is 2.5 mL/kg birth weight, administered as one or two aliquots depending upon the instillation procedure [see Dosage and Administration ( 2.4 )]. Up to two repeat doses of 1.25 mL/kg birth weight each may be administered at approximately 12-hour intervals in infants in whom RDS is considered responsible for their persisting or deteriorating respiratory status. The maximum recommended total dosage (sum of the initial and up to two repeat doses) is 5 mL/kg.","2.3 Preparation of the CUROSURF Suspension Remove the vial of CUROSURF suspension from a refrigerator at +2°C to +8°C (36°F to 46°F) and slowly warm the vial to room temperature before use. Visually inspect the CUROSURF suspension for discoloration prior to administration. The color of the CUROSURF suspension should be white to creamy white. Discard the CUROSURF vial if the suspension is discolored. Gently turn the vial upside-down, in order to obtain a uniform suspension. DO NOT SHAKE. Locate the notch (FLIP UP) on the colored plastic cap and lift the notch and pull upwards. Pull the plastic cap with the aluminum portion downwards. Remove the whole ring by pulling off the aluminum wrapper. Remove the rubber cap to extract content. Unopened, unused vials of CUROSURF suspension that have warmed to room temperature can be returned to refrigerated storage within 24 hours for future use. Do not warm to room temperature and return to refrigerated storage more than once. Protect from light."],"spl_product_data_elements":["Curosurf poractant alfa PORACTANT ALFA PORACTANT ALFA SODIUM CHLORIDE SODIUM BICARBONATE"],"dosage_forms_and_strengths":["2.4 Administration For endotracheal tube instillation using a 5 French end-hole catheter Slowly withdraw the entire contents of the vial of CUROSURF suspension into a 3 or 5 mL plastic syringe through a large-gauge needle (e.g., at least 20 gauge). Enter each single-use vial only once. Attach the 5 French end-hole catheter of appropriate length to position the catheter tip proximal to the distal portion of the endotracheal tube, to the syringe. Fill the catheter with CUROSURF suspension. Discard excess CUROSURF through the catheter so that only the dose to be given remains in the syringe. For the first dose: 1.25 mL/kg (birth weight) per aliquot For each repeated dose: 0.625 mL/kg (birth weight) per aliquot First aliquot of CUROSURF suspension: Position the infant in a neutral position (head and body in alignment without inclination), with either the right or left side dependent. Immediately before CUROSURF administration, ventilate the infant with supplemental oxygen sufficient to maintain SaO 2 > 92%. Insert the catheter into the endotracheal tube and instill the first aliquot of CUROSURF suspension. After the first aliquot is instilled, remove the catheter from the endotracheal tube and manually ventilate with supplemental oxygen until clinically stable. Second aliquot of CUROSURF suspension: When the infant is stable, reposition the infant such that the other side is dependent. Administer the remaining aliquot using the same procedures as the first aliquot. After completion of the dosing procedure, do not suction airways for 1 hour after surfactant instillation unless signs of significant airway obstruction occur [see Clinical Studies ( 14.1 )] . For endotracheal tube instillation using the secondary lumen of a dual lumen endotracheal tube Slowly withdraw the entire contents of the vial of CUROSURF suspension into a 3 or 5 mL plastic syringe through a large-gauge needle (e.g., at least 20 gauge). Do not attach 5 French end-hole catheter. Remove the needle and discard excess CUROSURF so that only the dose to be given remains in the syringe. Keep the infant in a neutral position (head and body in alignment without inclination). Administer CUROSURF suspension through the proximal end of the secondary lumen of the endotracheal tube as a single dose, given over 1 minute, and without interrupting mechanical ventilation. After completion of this dosing procedure, ventilator management may require transient increases in FiO 2 , ventilator rate, or PIP. Do not suction airways for 1 hour after surfactant instillation unless signs of significant airway obstruction occur.","3 DOSAGE FORMS AND STRENGTHS Intratracheal suspension: CUROSURF (poractant alfa) is a white to creamy white suspension available in: 120 mg/1.5 mL (80 mg/mL) single-dose vials 240 mg/3 mL (80 mg/mL) single-dose vials Intratracheal Suspension: 120 mg/1.5 mL (80 mg/mL) single-dose vials ( 3 ) 240 mg/3 mL (80 mg/mL) single-dose vials ( 3 )"],"use_in_specific_populations":["8 USE IN SPECIFIC POPULATIONS 8.4 Pediatric Use The safety and effectiveness of CUROSURF for the rescue treatment, including the reduction of mortality and pneumothoraces, of Respiratory Distress Syndrome (RDS) have been established in premature infants and the information on this use is discussed throughout the labeling. The safety and effectiveness of CUROSURF in the treatment of full term infants or older pediatric patients with respiratory failure has not been established."],"package_label_principal_display_panel":["1.5 mL vial label","Curosurf 1.5mL carton"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Studies to assess potential carcinogenic effects of CUROSURF have not been conducted. Poractant alfa was negative for genotoxicity in the following assays: bacterial reverse mutation assay (Ames test), gene mutation assay in Chinese hamster V79 cells, chromosomal aberration assay in Chinese hamster ovary cells, unscheduled DNA synthesis in HELA S3 cells, and in vivo mouse micronucleus assay. No studies to assess reproductive effects of CUROSURF have been performed."]},"tags":[{"label":"Surfactant","category":"class"},{"label":"Biologic","category":"modality"},{"label":"Endotracheal","category":"route"},{"label":"Suspension","category":"form"},{"label":"Active","category":"status"},{"label":"Respiratory distress syndrome in the newborn","category":"indication"},{"label":"Chiesi Usa Inc","category":"company"},{"label":"Approved 1990s","category":"decade"},{"label":"Pulmonary Surfactants","category":"pharmacology"},{"label":"Respiratory System Agents","category":"pharmacology"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"NEONATAL HYPOXIA","source":"FDA FAERS","actionTaken":"119 reports"},{"date":"","signal":"OFF LABEL USE","source":"FDA FAERS","actionTaken":"78 reports"},{"date":"","signal":"PULMONARY HAEMORRHAGE","source":"FDA FAERS","actionTaken":"78 reports"},{"date":"","signal":"BRADYCARDIA NEONATAL","source":"FDA FAERS","actionTaken":"50 reports"},{"date":"","signal":"ILL-DEFINED DISORDER","source":"FDA FAERS","actionTaken":"49 reports"},{"date":"","signal":"DRUG INEFFECTIVE","source":"FDA FAERS","actionTaken":"45 reports"},{"date":"","signal":"ENDOTRACHEAL INTUBATION COMPLICATION","source":"FDA FAERS","actionTaken":"34 reports"},{"date":"","signal":"PRODUCT COMPLAINT","source":"FDA FAERS","actionTaken":"34 reports"},{"date":"","signal":"PNEUMOTHORAX","source":"FDA FAERS","actionTaken":"33 reports"},{"date":"","signal":"INFANTILE APNOEA","source":"FDA FAERS","actionTaken":"30 reports"}],"commonSideEffects":[{"effect":"Intracranial Hemorrhage","drugRate":"51%","severity":"serious","_validated":true},{"effect":"Patent Ductus Arteriosus","drugRate":"60%","severity":"serious","_validated":true},{"effect":"Bronchopulmonary Dysplasia","drugRate":"22%","severity":"common","_validated":true},{"effect":"Acquired Septicemia","drugRate":"18%","severity":"common","_validated":true},{"effect":"Acquired Pneumonia","drugRate":"17%","severity":"common","_validated":true},{"effect":"Pneumothorax","drugRate":"36%","severity":"serious","_validated":true},{"effect":"Pulmonary Interstitial Emphysema","drugRate":"38%","severity":"serious","_validated":true},{"effect":"Pulmonary hemorrhage","drugRate":"reported","severity":"unknown"}],"specialPopulations":{"Paediatric use":"The safety and effectiveness of CUROSURF for the rescue treatment, including the reduction of mortality and pneumothoraces, of Respiratory Distress Syndrome (RDS) have been established in premature infants and the information on this use is discussed throughout the labeling.The safety and effectiveness of CUROSURF in the treatment of full term infants or older pediatric patients with respiratory failure has not been established."}},"trials":[],"aliases":[],"company":"Chiesi Usa Inc","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=PORACTANT ALFA","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T03:44:56.841492+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T03:45:08.240964+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-20T03:44:55.480159+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=PORACTANT ALFA","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T03:45:08.913174+00:00"},"mechanism.drugClass":{"url":"https://api.fda.gov/drug/label.json","method":"deterministic","source":"FDA Label (EPC)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:44:54.311502+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:44:54.311544+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:44:54.311558+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T03:45:10.420781+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1201622/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:45:09.429819+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"BLA020744","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:44:54.311564+00:00"}},"allNames":"curosurf","offLabel":[],"synonyms":["poractant alfa","curosurf"],"timeline":[{"date":"1999-11-18","type":"positive","source":"DrugCentral","milestone":"FDA approval (Chiesi Usa Inc)"}],"aiSummary":"Curosurf (PORACTANT ALFA) is a surfactant medication originally developed by CHIESI USA INC and currently owned by the same company. It is a small molecule drug that belongs to the surfactant class and was FDA approved in 1999 for the treatment of respiratory distress syndrome in newborns. Curosurf works by reducing the surface tension in the lungs, allowing for easier breathing and improving oxygenation. It is a patented medication with a commercial status that is not off-patent. Key safety considerations include the potential for allergic reactions and the need for careful dosing.","approvals":[{"date":"1999-11-18","orphan":true,"company":"CHIESI USA INC","regulator":"FDA"}],"brandName":"Curosurf","ecosystem":[{"indication":"Respiratory distress syndrome in the newborn","otherDrugs":[{"name":"beractant","slug":"beractant","company":"Abbvie"},{"name":"calfactant","slug":"calfactant","company":"Ony"},{"name":"cetyl alcohol","slug":"cetyl-alcohol","company":"Glaxosmithkline"},{"name":"colfosceril palmitate","slug":"colfosceril-palmitate","company":"Glaxosmithkline"}],"globalPrevalence":null}],"mechanism":{"moaClass":"Surfactant Activity","modality":"Biologic","drugClass":"Surfactant [EPC]","explanation":"Endogenous pulmonary surfactant reduces surface tension at the air-liquid interface of the alveoli during ventilation and stabilizes the alveoli against collapse at resting transpulmonary pressures. deficiency of pulmonary surfactant in preterm infants results in Respiratory Distress Syndrome (RDS) characterized by poor lung expansion, inadequate gas exchange, and gradual collapse of the lungs (atelectasis).CUROSURF compensates for the deficiency of surfactant and restores surface activity to the lungs of these infants.","oneSentence":"Curosurf works by reducing the surface tension in the lungs, allowing for easier breathing and improving oxygenation.","technicalDetail":"Curosurf (PORACTANT ALFA) is a synthetic surfactant that mimics the natural surfactant produced by the lungs. It works by reducing the surface tension in the lungs, which allows for easier expansion of the alveoli and improves gas exchange."},"commercial":{"launchDate":"1999","_launchSource":"DrugCentral (FDA 1999-11-18, CHIESI USA INC)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/5148","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=PORACTANT%20ALFA","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=PORACTANT ALFA","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T15:22:38.225389","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:45:16.647149+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[],"genericName":"poractant alfa","indications":{"approved":[{"name":"Respiratory distress syndrome in the newborn","source":"DrugCentral","snomedId":46775006,"regulator":"FDA"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT04545866","phase":"PHASE3","title":"The Budesonide in Babies (BiB) Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"NICHD Neonatal Research Network","startDate":"2021-04-01","conditions":["Bronchopulmonary Dysplasia (BPD)","Respiratory Distress Syndrome","Prematurity; Extreme","Neonatal"],"enrollment":642,"completionDate":"2026-12-17"},{"nctId":"NCT07350018","phase":"PHASE4","title":"Calfactant vs Poractant Alfa Using a Less Invasive Technique in Preterm Infants With Respiratory Distress Syndrome","status":"NOT_YET_RECRUITING","sponsor":"Uludag University","startDate":"2026-01-20","conditions":["Respiratory Distress Syndrome in Premature Infants","Respiratory Distress Syndrome (RDS)","Surfactant"],"enrollment":234,"completionDate":"2027-02-20"},{"nctId":"NCT04715373","phase":"NA","title":"LISA in the Delivery Room for Extremely Preterm Infants","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2021-06-22","conditions":["Extreme Prematurity","Respiratory Distress Syndrome"],"enrollment":60,"completionDate":"2025-04-08"},{"nctId":"NCT04209946","phase":"NA","title":"Early Caffeine and LISA Compared to Caffeine and CPAP in Preterm Infants","status":"COMPLETED","sponsor":"Sharp HealthCare","startDate":"2020-01-22","conditions":["Premature Lungs","Respiratory Distress Syndrome","Surfactant Deficiency Syndrome Neonatal"],"enrollment":180,"completionDate":"2025-11-10"},{"nctId":"NCT07271368","phase":"NA","title":"EXTERNAL NEGATIVE PRESSURE DURING LISA","status":"NOT_YET_RECRUITING","sponsor":"Charles University, Czech Republic","startDate":"2025-12-22","conditions":["Neonatology"],"enrollment":25,"completionDate":"2027-01-31"},{"nctId":"NCT07261787","phase":"PHASE4","title":"Duration of Surfactant Administration and Impact on Stabilisation of Vital Parameters in Very Preterm Neonates: 1 Minutes Versus 5 Minutes","status":"NOT_YET_RECRUITING","sponsor":"Medical University of Graz","startDate":"2025-12-01","conditions":["Neonates and Preterm Infants","Infant Respiratory Distress Syndrome","Surfactant Deficiency Syndrome Neonatal","Surfactant","Cerebral Oxygenation","Cerebral Oxygen Saturation"],"enrollment":76,"completionDate":"2028-12-01"},{"nctId":"NCT07098910","phase":"NA","title":"Surfactant Therapy Via Supraglottic Airway to Preterm Neonates With RDS in Vietnam","status":"RECRUITING","sponsor":"Karolinska Institutet","startDate":"2025-09-25","conditions":["Respiratory Distress Syndrome in Premature Infant"],"enrollment":440,"completionDate":"2029-03-30"},{"nctId":"NCT07176117","phase":"NA","title":"Surfactant Using a Supraglottic Airway Device in Late Preterm to Early Term Infants","status":"NOT_YET_RECRUITING","sponsor":"Sharp HealthCare","startDate":"2025-10-01","conditions":["Respiratory Distress Syndrome (Neonatal)","Surfactant"],"enrollment":422,"completionDate":"2031-06-30"},{"nctId":"NCT06606444","phase":"NA","title":"Feasibility Study of Placement and Surfactant Administration Through a Preterm Size Laryngeal Mask Airway in Very Low Birth Weight Neonates With Respiratory Distress Syndrome","status":"COMPLETED","sponsor":"Karolinska Institutet","startDate":"2024-09-20","conditions":["Respiratory Distress Syndrome, Newborn"],"enrollment":45,"completionDate":"2025-08-01"},{"nctId":"NCT06007547","phase":"PHASE4","title":"Prophylactic Minimally Invasive Surfactant Evaluation","status":"RECRUITING","sponsor":"Endeavor Health","startDate":"2024-01-01","conditions":["Respiratory Distress Syndrome, Newborn","Premature Birth"],"enrollment":200,"completionDate":"2027-07-31"},{"nctId":"NCT06074380","phase":"PHASE4","title":"Non Inferiority Trial Investigating Surfactants Administered Via MIST","status":"RECRUITING","sponsor":"Endeavor Health","startDate":"2024-01-01","conditions":["Respiratory Distress Syndrome"],"enrollment":262,"completionDate":"2027-12-01"},{"nctId":"NCT06557551","phase":"NA","title":"Prophylactic Surfactant by Thin Endotracheal Catheter for Preterm Infants At Birth: the ProTeCt Trial","status":"RECRUITING","sponsor":"University College Dublin","startDate":"2024-08-19","conditions":["Infant, Newborn, Diseases","Prematurity","Prematurity; Extreme","Respiratory Distress Syndrome in Premature Infant"],"enrollment":164,"completionDate":"2027-02-28"},{"nctId":"NCT06491901","phase":"NA","title":"Prospective, Non-Blinded, Randomized Controlled Trial on Early Administration of Pulmonary Surfactant Guided by Lung Ultrasound Scores in Very Preterm Infants.","status":"NOT_YET_RECRUITING","sponsor":"Peking University Third Hospital","startDate":"2024-08-01","conditions":["Early Administration of Pulmonary Surfactant Guided by Lung Ultrasound Scores in Very Preterm Infants"],"enrollment":60,"completionDate":"2025-05-31"},{"nctId":"NCT04315636","phase":"PHASE3","title":"Surfactant Nebulization for the Early Aeration of the Preterm Lung","status":"COMPLETED","sponsor":"University of Zurich","startDate":"2021-03-19","conditions":["Preterm Birth","Respiratory Distress Syndrome","Surfactant Deficiency Syndrome Neonatal"],"enrollment":32,"completionDate":"2022-01-16"},{"nctId":"NCT02772081","phase":"PHASE3","title":"A Study in Preterm Neonates With Respiratory Distress Syndrome (RDS) Comparing CUROSURF® Administration Through Less Invasive Surfactant Administration (LISA) and Conventional Administration","status":"TERMINATED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2021-05-18","conditions":["Respiratory Distress Syndrome (RDS)"],"enrollment":33,"completionDate":"2022-08-13"},{"nctId":"NCT04181255","phase":"PHASE1","title":"Cold Heart Study: A Randomized Pilot Trial of Surfactant Therapy","status":"TERMINATED","sponsor":"University of Michigan","startDate":"2020-02-25","conditions":["Congenital Heart Disease","Hypoplastic Left Heart Syndrome"],"enrollment":2,"completionDate":"2020-06-12"},{"nctId":"NCT04502433","phase":"PHASE2","title":"Poractant Alfa (Curosurf®)) -- Effect in Adult Patients Diagnosed With 2019 Novel Coronavirus (SARS-COV-19; (Covid-19)) Acute Respiratory Distress Syndrome (ARDS)","status":"TERMINATED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2021-01-06","conditions":["Acute Respiratory Distress Syndrome"],"enrollment":22,"completionDate":"2022-03-17"},{"nctId":"NCT03275415","phase":"PHASE4","title":"Intratracheal Budesonide/Surfactant Prevents BPD","status":"COMPLETED","sponsor":"Taipei Medical University","startDate":"2019-07-01","conditions":["Respiratory Distress Syndrome","Bronchopulmonary Dysplasia"],"enrollment":310,"completionDate":"2022-06-30"},{"nctId":"NCT05711966","phase":"NA","title":"Comparison of INRECSURE and LISA in Preterm Neonates With RDS","status":"RECRUITING","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2023-01-09","conditions":["Respiratory Distress Syndrome","Bronchopulmonary Dysplasia"],"enrollment":381,"completionDate":"2026-04-15"},{"nctId":"NCT01039285","phase":"PHASE4","title":"Exogenous Surfactant in Very Preterm Neonates in Prevention of Bronchopulmonary Dysplasia","status":"COMPLETED","sponsor":"Jean Michel Hascoet","startDate":"2009-12","conditions":["Infant, Premature, Diseases","Respiratory Distress Syndrome, Newborn","Bronchopulmonary Dysplasia"],"enrollment":118,"completionDate":"2022-06"},{"nctId":"NCT03235986","phase":"PHASE2","title":"A Study To InvestigateThe Safety, Tolerability And Efficacy Of Nebulised Curosurf® In Preterm Neonates With Respiratory Distress Syndrome (RDS)","status":"TERMINATED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2017-08-28","conditions":["Neonatal Respiratory Distress Syndrome"],"enrollment":166,"completionDate":"2020-05-05"},{"nctId":"NCT04825197","phase":"PHASE2","title":"Late Surfactant After a Recruitment Maneuver in Extremely Low Gestational Age Newborns - LATE-REC-SURF Trial","status":"UNKNOWN","sponsor":"VENTO GIOVANNI","startDate":"2021-12-01","conditions":["Bronchopulmonary Dysplasia","Chronic Pulmonary Insufficiency of Prematurity"],"enrollment":20,"completionDate":"2025-02-01"},{"nctId":"NCT04862377","phase":"PHASE3","title":"Intratracheal Budesonide With Surfactant to Prevent Bronchopulmmonary Dysplasia.","status":"NOT_YET_RECRUITING","sponsor":"Hospital Clinic of Barcelona","startDate":"2021-10-01","conditions":["Bronchopulmonary Dysplasia","Respiratory Distress Syndrome in Premature Infant","Prematurity"],"enrollment":50,"completionDate":"2026-04-01"},{"nctId":"NCT02452476","phase":"PHASE2","title":"A Double Blind, Randomized, Controlled Study to Evaluate CHF 5633 (Synthetic Surfactant) and Poractant Alfa in Neonates With Respiratory Distress Syndrome (RDS) (POC)","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2016-01-21","conditions":["Respiratory Distress Syndrome, Newborn"],"enrollment":123,"completionDate":"2018-05-24"},{"nctId":"NCT04199364","phase":"PHASE4","title":"Medium vs Low Oxygen Threshold for the Surfactant Administration","status":"UNKNOWN","sponsor":"Virgilio Paolo Carnielli","startDate":"2021-06-01","conditions":["Respiratory Distress Syndrome"],"enrollment":200,"completionDate":"2025-04-30"},{"nctId":"NCT03959384","phase":"PHASE3","title":"Efficacy and Safety of Curosurf® in Patients Invasively Ventilated for Severe Bronchiolitis Under 12 Months of Age","status":"TERMINATED","sponsor":"Azienda Ospedaliera Universitaria Integrata Verona","startDate":"2019-01-09","conditions":["Bronchiolitis, Viral"],"enrollment":9,"completionDate":"2021-04-09"},{"nctId":"NCT04384731","phase":"PHASE2","title":"Curosurf® in Adult Acute Respiratory Distress Syndrome Due to COVID-19","status":"UNKNOWN","sponsor":"Dr Christophe LENCLUD","startDate":"2020-05-29","conditions":["COVID-19","ARDS, Human"],"enrollment":20,"completionDate":"2021-07-31"},{"nctId":"NCT04073173","phase":"PHASE4","title":"Stress Assessment With and Without Analgesia During Surfactant Therapy in Preterm Infants.","status":"UNKNOWN","sponsor":"Virgilio Paolo Carnielli","startDate":"2020-11-01","conditions":["Respiratory Distress Syndrome in Premature Infants"],"enrollment":80,"completionDate":"2022-10-31"},{"nctId":"NCT00501982","phase":"PHASE4","title":"Efficacy of Combining Prophylactic Curosurf With Early Nasal CPAP in Delivery Room: the Curpap Study","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2007-03","conditions":["Respiratory Distress Syndrome, Newborn"],"enrollment":208,"completionDate":"2008-05"},{"nctId":"NCT02140580","phase":"PHASE4","title":"OPTIMIST-A Trial: Minimally-invasive Surfactant Therapy in Preterm Infants 25-28 Weeks Gestation on CPAP","status":"UNKNOWN","sponsor":"Menzies Institute for Medical Research","startDate":"2011-12","conditions":["Bronchopulmonary Dysplasia"],"enrollment":486,"completionDate":"2022-06"},{"nctId":"NCT01941524","phase":"PHASE4","title":"Brain Oxygenation and Function of Preterm Newborns During Administration of Two Different Surfactant Preparations","status":"COMPLETED","sponsor":"Poznan University of Medical Sciences","startDate":"2013-03-03","conditions":["Respiratory Distress Syndrome, Newborn","Respiratory Failure"],"enrollment":22,"completionDate":"2015-06-20"},{"nctId":"NCT03846960","phase":"NA","title":"Surfactant Administration Via Thin Catheter Using a Specially Adapted Video Laryngoscope","status":"UNKNOWN","sponsor":"HaEmek Medical Center, Israel","startDate":"2019-11-01","conditions":["Respiratory Distress Syndrome"],"enrollment":20,"completionDate":"2021-12"},{"nctId":"NCT03521063","phase":"PHASE4","title":"Efficacy of Adding Budesonide to Poractant Alfa to Prevent Bronchopulmonary Dysplasia.","status":"UNKNOWN","sponsor":"Hospital Central \"Dr. Ignacio Morones Prieto\"","startDate":"2018-01-01","conditions":["Bronchopulmonary Dysplasia","Infant,Premature","Respiratory Distress Syndrome"],"enrollment":108,"completionDate":"2019-12-31"},{"nctId":"NCT02482766","phase":"NA","title":"Efficacy of a New Technique -\"IN-REC-SUR-E\"- in Preterm Neonates With RDS","status":"COMPLETED","sponsor":"Catholic University of the Sacred Heart","startDate":"2015-11","conditions":["Respiratory Distress Syndrome","Hyaline Membrane Disease"],"enrollment":206,"completionDate":"2018-09-30"},{"nctId":"NCT03655457","phase":"NA","title":"Evaluation of the Efficacy of Surfaktant in Preterm Infants by Lung Ultrasound","status":"UNKNOWN","sponsor":"Zekai Tahir Burak Women's Health Research and Education Hospital","startDate":"2018-03-21","conditions":["Lung Ultrasound Scores"],"enrollment":64,"completionDate":"2019-02-28"},{"nctId":"NCT03385863","phase":"","title":"Efficacy of Surfactant and Perinatal Risk Factors in NRDS With Different Gestational Ages","status":"UNKNOWN","sponsor":"Daping Hospital and the Research Institute of Surgery of the Third Military Medical University","startDate":"2011-01-01","conditions":["Infant, Newborn, NRDS"],"enrollment":1500,"completionDate":"2018-03-01"},{"nctId":"NCT02013115","phase":"NA","title":"Curosurf/Budesonide for Infants With Respiratory Distress Syndrome","status":"COMPLETED","sponsor":"Daping Hospital and the Research Institute of Surgery of the Third Military Medical University","startDate":"2015-01-01","conditions":["Respiratory Distress Syndrome"],"enrollment":300,"completionDate":"2017-10-30"},{"nctId":"NCT01709409","phase":"PHASE3","title":"A Multi-center Trial to Determine if Curosurf® Reduces the Duration of Mechanical Ventilation in Very Preterm Infants","status":"COMPLETED","sponsor":"Ottawa Hospital Research Institute","startDate":"2013-03","conditions":["Respiratory Distress Syndrome"],"enrollment":88,"completionDate":"2016-08"},{"nctId":"NCT01615016","phase":"PHASE2","title":"MISurf Versus InSurE. A Comparison of Minimally Invasive Surfactant Application Techniques in Preterm Infants","status":"TERMINATED","sponsor":"Hamilton Health Sciences Corporation","startDate":"2012-07","conditions":["Hyaline Membrane Disease"],"enrollment":4,"completionDate":"2017-08-19"},{"nctId":"NCT02834624","phase":"NA","title":"Comparison of Curosurf and Infasurf in the Treatment of Preterm Infants With Respiratory Distress Syndrome","status":"COMPLETED","sponsor":"University of Missouri-Columbia","startDate":"2013-07","conditions":["Respiratory Distress Syndrome"],"enrollment":30,"completionDate":"2015-07"},{"nctId":"NCT01116921","phase":"NA","title":"Laryngeal Mask Airway (LMA) for Surfactant Administration in Neonates","status":"COMPLETED","sponsor":"University of Minnesota","startDate":"2011-02","conditions":["Respiratory Distress Syndrome"],"enrollment":103,"completionDate":"2015-04"},{"nctId":"NCT02041546","phase":"PHASE4","title":"Lung Lavage With Dilute Poractant Alfa for Meconium Aspiration Syndrome","status":"COMPLETED","sponsor":"Zekai Tahir Burak Women's Health Research and Education Hospital","startDate":"2013-09","conditions":["Meconium Aspiration Syndrome"],"enrollment":30,"completionDate":"2014-12"},{"nctId":"NCT02825953","phase":"NA","title":"Does The Surfactant Administration by Aerosolization Effective?","status":"UNKNOWN","sponsor":"nihat demir","startDate":"2016-01","conditions":["Respiratory Distress Syndrome","Surfactant Administration by Aerosolization"],"enrollment":75,"completionDate":"2017-01"},{"nctId":"NCT01306240","phase":"PHASE3","title":"Surfactant Versus Nasal Continuous Positive Airway Pressure (nCPAP) for Respiratory Distress Syndrome in the Newborn ≥ 35 Weeks of Gestation","status":"TERMINATED","sponsor":"Centre Hospitalier Universitaire, Amiens","startDate":"2011-03","conditions":["Acute Respiratory Distress Syndrome"],"enrollment":19,"completionDate":"2012-10"},{"nctId":"NCT02305160","phase":"PHASE2,PHASE3","title":"A Multicenter, Randomized, Open Label Trial of a New Animal Extracted Surfactant to Treat RDS in Preterm Infants","status":"COMPLETED","sponsor":"University of Sao Paulo","startDate":"2005-04","conditions":["Respiratory Distress Syndrome"],"enrollment":327,"completionDate":"2007-07"},{"nctId":"NCT01741129","phase":"PHASE4","title":"Comparison of Effectiveness of Nasal CPAP and Nasal IMV in Early Rescue Surfactant Treatment in Preterm Infants","status":"COMPLETED","sponsor":"Mehmet Yekta","startDate":"2012-11","conditions":["Noninvasive Ventilation for Respiratory Distress Syndrome"],"enrollment":200,"completionDate":"2013-11"},{"nctId":"NCT01537354","phase":"NA","title":"Comparison in Pulmonary Compliance Between Curosurf and Survanta in Preterm Infants With Respiratory Distress Syndrome","status":"WITHDRAWN","sponsor":"University of Michigan","startDate":"2012-06","conditions":["Respiratory Distress Syndrome"],"enrollment":0,"completionDate":""},{"nctId":"NCT01923844","phase":"PHASE4","title":"Effects of Bolus Surfactant Therapy on Peripheral Perfusion Index and Tissue Carbon Monoxide","status":"COMPLETED","sponsor":"Ege University","startDate":"2012-03","conditions":["Respiratory Distress Syndrome"],"enrollment":48,"completionDate":"2013-04"},{"nctId":"NCT01860014","phase":"NA","title":"Comparison of Two Different Natural Surfactants in the Treatment of Pulmonary Hemorrhage","status":"COMPLETED","sponsor":"Dr. Sami Ulus Children's Hospital","startDate":"2010-03","conditions":["Pulmonary Hemorrhage"],"enrollment":20,"completionDate":"2011-03"},{"nctId":"NCT01852461","phase":"NA","title":"Perfusion Index Variability in Respiratory Distress Syndrome","status":"COMPLETED","sponsor":"Dr. Sami Ulus Children's Hospital","startDate":"2011-08","conditions":["Poor Peripheral Perfusion"],"enrollment":92,"completionDate":"2012-12"},{"nctId":"NCT00751959","phase":"NA","title":"Surfactant Application During Spontaneous Breathing With Continuous Positive Airway Pressure (CPAP) in Premature Infants < 27 Weeks","status":"COMPLETED","sponsor":"University of Cologne","startDate":"2009-04","conditions":["Respiratory Distress Syndrome, Newborn"],"enrollment":213,"completionDate":"2012-06"},{"nctId":"NCT01102543","phase":"","title":"Observational Study on the Prophylactic Use of Curosurf in Neonatal Respiratory Distress Syndrome (RDS)","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2010-03","conditions":["Respiratory Distress Syndrome, Newborn"],"enrollment":972,"completionDate":"2011-03"},{"nctId":"NCT00767039","phase":"PHASE4","title":"Curosurf and Survanta Treatment(CAST)of RDS in Very Premature Infants","status":"TERMINATED","sponsor":"Alan Fujii","startDate":"2005-01","conditions":["Prematurity","Respiratory Distress Syndrome","Patent Ductus Arteriosus"],"enrollment":52,"completionDate":"2009-01"},{"nctId":"NCT01294852","phase":"NA","title":"Comparison of Two Strategies for Surfactant Prophylaxis in Premature Infants","status":"UNKNOWN","sponsor":"Ankara University","startDate":"2010-01","conditions":["Premature Birth","Premature Lungs"],"enrollment":100,"completionDate":"2012-06"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Endotracheal","formulation":"Suspension","formulations":[{"form":"SUSPENSION","route":"ENDOTRACHEAL","productName":"Curosurf"}]},"crossReferences":{"MMSL":"31530","NDDF":"005782","UNII":"KE3U2023NP","VANDF":"4021204","RXNORM":"236381","UMLSCUI":"C0771648","chemblId":"CHEMBL1201622","ChEMBL_ID":"CHEMBL1201622","KEGG_DRUG":"D08402","DRUGBANK_ID":"DB09113","SNOMEDCT_US":"116075008","MESH_SUPPLEMENTAL_RECORD_UI":"C068291"},"formularyStatus":[],"originalProduct":{"form":"SUSPENSION","route":"ENDOTRACHEAL","company":"Chiesi USA, Inc.","brandName":"Curosurf","isOriginal":true,"marketingStatus":"BLA"},"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"1999-","companyName":"Chiesi Usa Inc","relationship":"Original Developer"}],"publicationCount":159,"therapeuticAreas":["Respiratory"],"biosimilarFilings":[],"originalDeveloper":"Chiesi Usa Inc","recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"approved","companyName":"Chiesi Usa Inc","companyId":"chiesi-usa-inc","modality":"Biologic","firstApprovalDate":"1999","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1999-11-18T00:00:00.000Z","mah":"CHIESI USA INC","brand_name_local":null,"application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2004-02-17T00:00:00.000Z","mah":"CHIESI USA INC","brand_name_local":null,"application_number":"BLA020744"},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":2,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:45:16.647149+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}